# A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

> **NCT05849727** · PHASE2 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 195 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** TQH3821 tablets 200 mg
- **DRUG:** TQH3821 tablets matching placebo

## Key facts

- **NCT ID:** NCT05849727
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-30
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 195 (ACTUAL)
- **Why stopped:** Per sponsor request.
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05849727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05849727, "A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05849727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*